Renowned Footballer David Beckham Invests In Small Health & Wellness Firm Prenetics
Renowned Footballer David Beckham Invests In Small Health & Wellness Firm Prenetics
On Thursday, Prenetics Global Limited (NASDAQ:PRE) announced that former international footballer, entrepreneur, and philanthropist David Beckham has become a strategic investor in the business.
周四,Prenetics Global Limited(纳斯达克股票代码:PRE)宣布,前国际足球运动员、企业家和慈善家大卫·贝克汉姆已成为该业务的战略投资者。
Prenetics and Beckham will become co-founding partners of a new health and wellness brand, IM8, which will focus on consumer health products, with details to be announced at a later date.
Prenetics和Beckham将成为新的健康和保健品牌IM8的共同创始合作伙伴,该品牌将专注于消费类健康产品,细节将在稍后公布。
Beckham said, "Throughout my life and career, I've been fortunate to have access to the best medical professionals, nutrition experts, and fitness coaches. Their guidance has been crucial to my health and well-being. That's why I am excited to be working with Prenetics—a company dedicated to innovative, world-leading scientific advancements in health—as a co-founding partner and ambassador for IM8."
贝克汉姆说:“在我的一生和职业生涯中,我很幸运能接触到最好的医疗专业人员、营养专家和健身教练。他们的指导对我的健康和福祉至关重要。这就是为什么我很高兴能与Prenetics合作,Prenetics是一家致力于创新的、世界领先的健康科学进步的公司,成为IM8的共同创始合作伙伴和大使。”
Prenetics is a health sciences company. IM8, a new health and wellness brand, leads consumer initiatives.
Prenetics 是一家健康科学公司。IM8是一个新的健康和保健品牌,引领消费者计划。
The clinical division is led by Insighta, a $200 million joint venture with renowned scientist Prof. Dennis Lo, focused on multi-cancer early detection technologies.
该临床部门由Insighta领导,Insighta是一家与著名科学家罗丹尼斯·罗教授合资的2亿美元合资企业,专注于多癌症早期检测技术。
Prenetics reported first-quarter revenue of $6.4 million, an increase of 30.2% compared to the first quarter of 2023.
Prenetics公布的第一季度收入为640万美元,与2023年第一季度相比增长了30.2%。
Danny Yeung, CEO and Co-Founder of Prenetics, remarked: "The first quarter of 2024 marked a good start for our company, showcasing solid growth in revenue and gross profit...Our purpose remains dedicated to our science-first approach in our pivot to consumer healthcare to broaden accessibility to science-based health and wellness."
Prenetics首席执行官兼联合创始人杨丹尼表示:“2024年第一季度标志着我们公司的良好开端,收入和毛利润稳步增长... 我们的目标仍然是致力于以科学为先的方法,转向消费者医疗保健,以扩大以科学为基础的健康和保健的可及性。”
The company reported cash and other short-term assets of $86.6 million as of March 31, 2024.
截至2024年3月31日,该公司报告的现金和其他短期资产为8,660万美元。
Price Action: PRE shares are up 1.01% at $6.06 at the last check on Thursday.
价格走势:在周四的最后一次检查中,PRE股价上涨1.01%,至6.06美元。
- EXCLUSIVE: Vivani Medical Outlines Plans To Kickstart First Clinical Study For Miniature GLP-1 Obesity Implant Program This Year
- 独家:Vivani Medical 概述了今年启动微型 GLP-1 肥胖植入计划的首次临床研究的计划
Photo via Shutterstock
照片来自 Shutterstock